NCT05030740 is a clinical trial in Pathology of the Thoracic Aorta, sponsored by Vascutek Ltd..

Who is sponsoring NCT05030740?

NCT05030740 is sponsored by Vascutek Ltd..

What condition does NCT05030740 study?

NCT05030740 studies Pathology of the Thoracic Aorta, Aneurysm Thoracic, Pseudo-aneurysm, Thoracic, Dissection of Thoracic Aorta, Intramural Haematoma of Thoracic Aorta, Penetrating Ulcer of Aorta (Disorder), Rupture of the Isthmus.

Is NCT05030740 still recruiting?

NCT05030740 is currently completed. Last updated 19 February 2025.

Last reviewed 2025-02-19 · How we verify

NCT05030740

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

French Assessment of the Relay Plus and Relay NBS Plus Thoracic Stent-Graft

Completed Last updated 19 February 2025

What this trial tests

trial in Pathology of the Thoracic Aorta in 170 participants. Completed in 15 January 2024.

Timeline

18 December 2014

Primary endpoint
15 January 2024

15 January 2024

Quick facts

Lead sponsor	Vascutek Ltd.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	170
Start date	18 December 2014
Primary completion	15 January 2024
Estimated completion	15 January 2024
Sites	10 locations across France

Conditions studied

Pathology of the Thoracic Aorta — all drugs for Pathology of the Thoracic Aorta →
Aneurysm Thoracic — all drugs for Aneurysm Thoracic →
Pseudo-aneurysm, Thoracic — all drugs for Pseudo-aneurysm, Thoracic →
Dissection of Thoracic Aorta — all drugs for Dissection of Thoracic Aorta →

Sponsor

Vascutek Ltd. — full company profile →

Who can join

Under 80, any sex, with Pathology of the Thoracic Aorta or Aneurysm Thoracic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Stent treatment of thoracic aortic pathologies, including aneurysms, pseudo-aneurysms, dissections, intramural hematomas, penetrating ulcers and ruptures of the isthmus, seems to provide a likely benefit compared to surgery in terms of surgical mortality and severe morbidity. However, the data concerning the long-term fate of these stents are insufficient. For this reason, the French National Health Authority (HAS) requests a 5-year follow-up in relation to the renewal of insurance reimbursement for these stent-grafts. Therefore, this long-term observational study has been set up.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Vascutek Ltd. trials

Trials by the same sponsor.

NCT03180996 — Global Fenestrated Anaconda Clinical STudy · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05030740 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vascutek Ltd.
Last refreshed: 19 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05030740.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing